• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NeoPharm

NeoPharm

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Research and Markets: Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles

    Research and Markets: Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles

  2. Stock Star Rating Performance Update

    We lost some ground during the second quarter of 2006, but the performance of our top-rated stocks continues to be solid. More importantly, we added a large number of new 5-star stocks to our benchmark portfolio during the market's swoon, and any opportunity to buy companies at bargain prices is a ...

  3. Stock Star Rating Performance Review

    Our top-rated stocks continue to do well, turning in very respectable performance in 2006. I'm happy that our patient strategy of recommending only stocks trading at a price that includes a reasonable margin of safety is paying off nicely for consumers of our research. As we have for the past few ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.